These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Husková Z, Kramer HJ, Thumová M, Vanourková Z, Bürgelová M, Teplan V, Malý J, Cervenka L. Kidney Blood Press Res; 2006; 29(2):74-83. PubMed ID: 16651849 [Abstract] [Full Text] [Related]
44. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. Kidney Int; 1998 Aug; 54(2):343-52. PubMed ID: 9690200 [Abstract] [Full Text] [Related]
46. Circadian rhythms in renal function in hypertensive TGR(mRen-2)27 rats and their normotensive controls. Pons M, Schnecko A, Witte K, Lemmer B, Waterhouse JM, Cambar J. Am J Physiol; 1996 Oct; 271(4 Pt 2):R1002-8. PubMed ID: 8897993 [Abstract] [Full Text] [Related]
47. Angiotensin peptides acting at rostral ventrolateral medulla contribute to hypertension of TGR(mREN2)27 rats. Fontes MA, Baltatu O, Caligiorne SM, Campagnole-Santos MJ, Ganten D, Bader M, Santos RA. Physiol Genomics; 2000 Apr 27; 2(3):137-42. PubMed ID: 11015592 [Abstract] [Full Text] [Related]
48. Reduction of oxidative stress does not attenuate the development of angiotensin II-dependent hypertension in Ren-2 transgenic rats. Kopkan L, Husková Z, Vanourková Z, Thumová M, Skaroupková P, Malý J, Kramer HJ, Dvorák P, Cervenka L. Vascul Pharmacol; 2009 Apr 27; 51(2-3):175-81. PubMed ID: 19539780 [Abstract] [Full Text] [Related]
50. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA. J Pharmacol Exp Ther; 1998 Nov 27; 287(2):567-77. PubMed ID: 9808682 [Abstract] [Full Text] [Related]
51. Role of the circulating renin-angiotensin system in the pathogenesis of hypertension in transgenic rats. TGR(mREN2)27. Peters J, Hilgers KF, Maser-Gluth C, Kreutz R. Clin Exp Hypertens; 1996 Oct 27; 18(7):933-48. PubMed ID: 8886477 [Abstract] [Full Text] [Related]
52. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects. Lachurié ML, Azizi M, Guyene TT, Alhenc-Gelas F, Ménard J. Circulation; 1995 Jun 15; 91(12):2933-42. PubMed ID: 7796503 [Abstract] [Full Text] [Related]
53. Increased expression of angiotensin peptides in the brain of transgenic hypertensive rats. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM, Brosnihan KB. Peptides; 1994 Jun 15; 15(5):919-26. PubMed ID: 7984514 [Abstract] [Full Text] [Related]
54. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. Böhm M, Lee M, Kreutz R, Kim S, Schinke M, Djavidani B, Wagner J, Kaling M, Wienen W, Bader M. J Hypertens; 1995 Aug 15; 13(8):891-9. PubMed ID: 8557967 [Abstract] [Full Text] [Related]
55. [A comparative study of cardiac function in transgenic hypertensive rats, in spontaneously hypertensive rats and in normotensive rats]. Bohlender J, Hildenbrand U, Schlegel WP, Hempel P, Nissen E, Krause EG, Bartel S. Arch Mal Coeur Vaiss; 2000 Aug 15; 93(8):993-6. PubMed ID: 10989744 [Abstract] [Full Text] [Related]
56. Insulin resistance and hypertension: studies in transgenic hypertensive TGR(mREN-2)27 rats. Vettor R, Cusin I, Ganten D, Rohner-Jeanrenaud F, Ferrannini E, Jeanrenaud B. Am J Physiol; 1994 Dec 15; 267(6 Pt 2):R1503-9. PubMed ID: 7810759 [Abstract] [Full Text] [Related]
58. Reciprocal feedback regulation of kidney angiotensinogen and renin mRNA expressions by angiotensin II. Schunkert H, Ingelfinger JR, Jacob H, Jackson B, Bouyounes B, Dzau VJ. Am J Physiol; 1992 Nov 15; 263(5 Pt 1):E863-9. PubMed ID: 1443118 [Abstract] [Full Text] [Related]
59. Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Campbell DJ, Karam H, Ménard J, Bruneval P, Mullins JJ. Hypertension; 2009 Dec 15; 54(6):1248-53. PubMed ID: 19841286 [Abstract] [Full Text] [Related]
60. Intrarenal alterations of the angiotensin-converting enzyme type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. Husková Z, Kopkan L, Červenková L, Doleželová Š, Vaňourková Z, Škaroupková P, Nishiyama A, Kompanowska-Jezierska E, Sadowski J, Kramer HJ, Červenka L. Clin Exp Pharmacol Physiol; 2016 Apr 15; 43(4):438-49. PubMed ID: 26833491 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]